Harrison School of Pharmacy
Faculty and Staff Directory
Gilliland and Franklin Professor
Departments: Drug Discovery and Development
Harrison School of Pharmacy
3211g Walker Building
Auburn, AL 36849
- A.B., Biology - Wabash, 1987
- M.Phil., Human Genetics - Yale
- Ph.D., Genetics - Yale, 1993
- Postdoc, Pathology – Yale, 1993-97
- Howard Hughes Medical Institute Predoctoral Fellow, Yale University, 1988-1993
- DoD Breast Cancer Research Program Postdoctoral Fellow, Yale University, 1994-97
- Assistant/Associate Professor, College of Pharmacy, Purdue University, 1997-2010
- Assistant/Associate Professor, Center for Cancer Research, Purdue University, 1997-2010
- Associate Dean for Research and Graduate Programs, Auburn University, 2010-2018
- Gilliland and Franklin Professor, Harrison School of Pharmacy, Auburn University, 2010-present
We study the Epidermal Growth Factor (EGF) family of peptide hormones and their receptors, the ErbB receptor tyrosine kinases. This network regulates the proliferation and differentiation of epithelial cells and deregulated signaling by this network contributes to human tumorigenesis and increased tumor cell invasiveness, metastatic potential, and chemoresistance. Consequently, we seek to understand the mechanism by which this network regulates cell function, with the ultimate goal being the development of novel cancer treatments.
ErbB4 and Epithelial Tumors – Activating (gain-of-function) mutations in ErbB4 are observed in a variety of epithelial tumors, indicating that ErbB4 functions as an oncogene. On the other hand, ErbB4 expression is lost in some types of epithelial tumors, indicating that ErbB4 is coupled to tumor suppression. Thus, we are using various expression systems, analytical approaches, ErbB4 ligands, and ErbB4 mutants to characterize ErbB4 coupling to tumor suppression and malignant phenotypes [41, 44, 50]. We are focused on deciphering the mechanisms by which ErbB4 can be coupled to these divergent responses [27, 41, 44, 50, 53]. We are also pursuing the discovery and development of novel ErbB4 agonists and antagonists that can be used to pharmacologically probe ErbB4 function in human malignancies and hold potential for the treatment of ErbB4-dependent tumors [30, 36, 42, 46].
EGF Family Hormones - In collaboration with investigators throughout the world we are characterizing the biological activities of EGF family hormones and we are identifying factors that regulate the affinity, potency, and efficacy (intrinsic) of these peptide growth factors [30, 36, 39, 40, 42, 45, 46, 48, 51]. Such insights may lead to the development of partial agonists whose antagonistic activities can be used to treat ErbB-dependent epithelial tumors .
#Indicates a publication that contributes to the Google Scholar i10-Index.
*Indicates a publication that contributes to the Google Scholar H-index
#*27. DJ Riese II, RM Gallo, and J Settleman. Mutational activation of ErbB receptor tyrosine kinases: Insights into mechanisms of signal transduction and tumorigenesis. Bioessays 29: 558-565 (2007). PMID: 17508401.
#30. KJ Wilson, CP Mill, EM Cameron, SS Hobbs, RP Hammer, and DJ Riese II. Interconversion of Neuregulin2 full and partial agonists for ErbB4. Biochem Biophys Res Com 364: 351-357 (2007). PMID: 17945187.
#*36. KJ Wilson, JL Gilmore, J Foley, MA Lemmon, and DJ Riese II. Functional selectivity of EGF Family Peptide Growth Factors: Implications for Cancer. Pharmacol Ther 122: 1-8 (2009). PMID: 19135477.
#39. JL Gilmore, RM Gonterman, K Menon, G Lorch, DJ Riese II, A Robling, and J Foley. Reconstitution of amphiregulin-EGFR signaling in lung squamous carcinomas activates PTHrP gene expression and cancer-mediated diseases of the bone. Mol Cancer Res 7: 1714-1728 (2009). PMID: 19825997.
#*40. J Foley, NK Nickerson, S Nam, KT Allen, JL Gilmore, KP Nephew, and DJ Riese II. EGFR signaling in breast cancer: Bad to the bone? Sem Cell Dev Biol 21: 951-960 (2010). PMID 20813200.
#41. CP Mill, K Gettinger, and DJ Riese II. Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines. Exp Cell Res 317: 392-404 (2011). PMID: 21110957.
#42. DJ Riese II. Ligand-based receptor tyrosine kinase partial agonists: New paradigm for cancer drug discovery? Expert Opin Drug Disc 6: 185-193 (2011). PMID: 21532939.
#44. CP Mill, MD Zordan, SM Rothenberg, J Settleman, JF Leary, and DJ Riese II. ErbB2 is necessary for ErbB4 ligands to stimulate oncogenic activities in models of human breast cancer. Genes & Cancer 2: 792-804 (2011). PMID: 22393464.
#*45. KJ Wilson, CP Mill, S Lambert, J Buchman, TR Wilson, V Hernandez-Gordillo, RM Gallo, Laura MC Ades, J Settleman, and DJ Riese II. EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling. Growth Factors 30: 107-116 (2012). PMID: 22260327.
46. KJ Wilson, CP Mill, RM Gallo, EM Cameron, H VanBrocklin, J Settleman, and DJ Riese II. The Q43L mutant of Neuregulin 2beta is a pan-ErbB receptor antagonist. Biochem J 443: 133-144 (2012). PMID: 22216880.
#48. NK Nickerson, CP Mill, HJ Wu, DJ Riese II, and J Foley. Autocrine-derived epidermal growth factor receptor ligands contribute to recruitment of tumor-associated macrophage and growth of basal breast cancer cells in vivo. Oncol Res 20: 303-17 (2013). PMID: 23879171.
50. RM Gallo, IN Bryant, CP Mill, S Kaverman, and DJ Riese II. Multiple functional motifs are required for the tumor suppressor activity of a constitutively-active ErbB4 mutant. J Cancer Res Ther Oncol 1: 104 (2013). PMID: 24791013.
#*51. DJ Riese II and RL Cullum. Epiregulin: Roles in Normal Physiology and Cancer. Sem Cell Dev Biol. 28: 49-56 (2014). PMID 24631357.
53. FML Kabir, P DeInnocentes, P Agarwal, CP Mill, DJ Riese II, and RC Bird. Estrogen Receptor-alpha, Progesterone Receptor and c-erbB/HER-Family Receptor mRNA Detection and Phenotype Analysis in Spontaneous Canine Models of Breast Cancer. Journal of Veterinary Science 18: (02) 149-158 (2017). PMID: 27515268.
Last Updated: February 21, 2020